Screener
4D Molecular Therapeutics FDMT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's EBITDA margin?
- 4D Molecular Therapeutics (FDMT) reported EBITDA margin of -214.6% in Q1 2026.
- How has 4D Molecular Therapeutics's EBITDA margin changed year-over-year?
- 4D Molecular Therapeutics's EBITDA margin increased by 100.0% year-over-year, from -864,326.1% to -214.6%.
- What is the long-term trend for 4D Molecular Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's EBITDA margin has grown at a -12.1% compound annual growth rate (CAGR), from -378.5% to -199%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about 4D Molecular Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude